A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Launched by ALNYLAM PHARMACEUTICALS · May 20, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin
• • Has mean systolic office blood pressure (SBP) of \>130 and \<=165 mmHg by automated office blood pressure measurement, after a minimum of 3 weeks of washout if taking hypertensive medication
• • Has 24-hour mean SBP ≥130 mmHg by ambulatory blood pressure monitoring (ABPM), without antihypertensive medication
• Exclusion Criteria:
• • Has secondary hypertension, symptomatic orthostatic hypotension
• • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2× upper limit of normal (ULN)
• • Has elevated serum potassium \>5 mmol/L
• • Has estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2
• • Has received an investigational agent within the last 30 days
• • Has Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus or newly diagnosed Type 2 diabetes mellitus
• • Has history of intolerance to SC injection(s)

Trial Officials